B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 13.9 HKD 17% Market Closed
Market Cap: 5.6B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Biocytogen Pharmaceuticals Beijing Co Ltd stock under the Base Case scenario is 14.07 HKD. Compared to the current market price of 13.9 HKD, Biocytogen Pharmaceuticals Beijing Co Ltd is Undervalued by 1%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
14.07 HKD
Undervaluation 1%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

5.3
P/S
P/S
Price to Sales
5.3
vs History
23
vs Industry
51
Median 3Y
3.4
Median 5Y
3.4
Industry
6.9
Forward
3.9
More Details
155.3
P/E
P/E
Price to Earnings
155.3
vs History
2
vs Industry
Median 3Y
-10.6
Median 5Y
-10.6
Industry
22.4
Forward
35.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-94.1
Median 5Y
-94.1
Industry
19.1
More Details
180.3
P/FCFE
P/FCFE
Price to FCFE
180.3
vs History
2
vs Industry
1
Median 3Y
-27.5
Median 5Y
-27.5
Industry
23.2
More Details
6.2
P/B
P/B
Price to Book Value
6.2
vs History
41
vs Industry
12
Median 3Y
5.3
Median 5Y
5.3
Industry
2.5
More Details
5.3
EV/S
EV/S
Enterprise Value to Sales
5.3
vs History
23
vs Industry
43
Median 3Y
3.4
Median 5Y
3.4
Industry
7.5
Forward
3.9
More Details
6.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.8
vs History
26
vs Industry
39
Median 3Y
4.5
Median 5Y
4.5
Industry
8.9
More Details
34.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
34.2
vs History
2
vs Industry
Median 3Y
-18.1
Median 5Y
-18.1
Industry
4
Forward
16.3
More Details
34.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
34.2
vs History
2
vs Industry
Median 3Y
-14.3
Median 5Y
-14.3
Industry
3.7
Forward
27.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-91
Median 5Y
-91
Industry
4.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-30.4
Median 5Y
-30.4
Industry
3.4
More Details
2.7
EV/IC
EV/IC
Enterprise Value to IC
2.7
vs History
41
vs Industry
39
Median 3Y
2.3
Median 5Y
2.3
Industry
4.6
More Details

Multiples Across Competitors

Competitors Multiples
Biocytogen Pharmaceuticals Beijing Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
5.6B HKD 5.3 155.3 34.2 34.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 047 871.8 -166 577.3 -202 278 -199 969.8
US
Abbvie Inc
NYSE:ABBV
350.4B USD 6.2 82.7 16.3 24.6
US
Amgen Inc
NASDAQ:AMGN
151B USD 4.5 36.9 15.2 26.9
US
Gilead Sciences Inc
NASDAQ:GILD
129.2B USD 4.5 269.1 10.6 13.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.8B USD 11.7 -240.4 26.3 27.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 010.1 -512.9 -558.5 -543.6
AU
CSL Ltd
ASX:CSL
124.8B AUD 5.3 29.3 18 22.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
66.4B USD 4.7 15 9.5 10.6
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.4 -63.9 -57.7
NL
argenx SE
XBRU:ARGX
35.1B EUR 18.2 47.7 -2 697.2 -1 808.3
P/S Multiple
Revenue Growth P/S to Growth
CN
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Average P/S: 3 186 360.1
5.3
24%
0.2
FR
Pharnext SCA
OTC:PNEXF
35 047 871.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.2
7%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
2 010.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.3
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.7
6%
0.8
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
18.2
39%
0.5
P/E Multiple
Earnings Growth PEG
CN
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Average P/E: 90.9
155.3
112%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 577.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
82.7
87%
1
US
Amgen Inc
NASDAQ:AMGN
36.9
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
269.1
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -240.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.9 N/A N/A
AU
CSL Ltd
ASX:CSL
29.3
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A
NL
argenx SE
XBRU:ARGX
47.7
28%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Average EV/EBITDA: 18.6
34.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 278 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
18%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.5 N/A N/A
AU
CSL Ltd
ASX:CSL
18
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.5
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 697.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Average EV/EBIT: 22.8
34.2
34%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 969.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -543.6 N/A N/A
AU
CSL Ltd
ASX:CSL
22.5
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.6
13%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 808.3 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.